SCHEDULE: Rubric Capital Management and David Rosen Disclose Passive Stake in Ovid Therapeutics

Rubric Capital Management LP and David Rosen have filed an amended Schedule 13G, reporting a 0.67% passive beneficial ownership stake in Ovid Therapeutics Inc. as of June 30, 2025.

Summary

• Rubric Capital Management LP and David Rosen collectively hold 478,533 shares of Ovid Therapeutics Inc. common stock.
• This ownership represents 0.67% of Ovid Therapeutics Inc.'s total outstanding common stock.
• The percentage of ownership is calculated based on 71,109,514 shares of common stock outstanding as of May 19, 2025, as reported by the Issuer.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported beneficial ownership position.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of passive beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

A Schedule 13G filing indicates a passive investment by an institutional investor or group, signifying that the holder does not intend to influence or change control of the company. This type of filing provides transparency regarding significant ownership stakes in publicly traded companies, particularly for those holding less than 20% and not seeking control.

Stakeholder Impact

• Primarily impacts shareholders by providing transparency regarding significant passive ownership stakes, which can offer insights into institutional interest in the company.

Key Dates

Keywords

Ovid Therapeutics, Rubric Capital Management, David Rosen, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Passive Investment